NDA Clinical Briefing Package Submitted to the US FDA
Telix Pharmaceuticals announces that it has submitted a complete clinical briefing package to the US FDA for its first product…
Read moreNews & Views
ZIRCON Phase 3 IND Submitted to the US FDA
Telix Pharmaceuticals Limited announces that it has submitted a Phase 3 IND application to the FDA for…
Read more
TLX101 for Brain Cancer IPAX-1 Study Update
Telix Pharmaceuticals has released an update on the progress of its TLX101 product in the treatment of glioblastoma…
Read more
University of Melbourne collaboration with Telix receives Cancer Australia research grant
News,
Telix Pharmaceuticals announces University of Melbourne collaboration with Telix receives Cancer Australia research…
Read more
Telix Pharmaceuticals and ATONCO Partner for Bladder Cancer
Telix Pharmaceuticals Limited and French company ATONCO S.A.S are pleased to announce they have entered into a Licence and Development Agreement that will enable ATONCO to investigate the use of Telix’s…
Read more
Webcast of CEO’s presentation to Jefferies 2019 London Healthcare Conference
Telix Pharmaceuticals Limited is pleased to announce that Group CEO, Dr. Christian Behrenbruch, presented at Jefferies 2019 London Healthcare Conference….
Read more Dr. Christian Behrenbruch, CEO of Telix Pharmaceuticals Limited, to speak at Jefferies 2019 London Healthcare Conference
Dr. Christian Behrenbruch, CEO of Telix Pharmaceuticals Limited will speak at Jefferies 2019 London Healthcare Conference. This year marks the 10th anniversary of now the largest healthcare-dedicated conference in Europe,…
Read more
Telix Pharmaceuticals Program Update Q3 2019
Telix Pharmaceuticals Limited is pleased to release a Clinical Trial Program Update for Q3,…
Read more
Telix Pharmaceuticals and AusHealth to Partner on Novel Therapeutics for Lung, Ovarian Cancer
Telix Pharmaceuticals Limited has today announced that Telix and AusHealth have entered into a collaboration and technology licensing agreement for a novel Molecularly Targeted Radiation (MTR) platform called APOMAB® intended for the…
Read more
Telix Pharmaceuticals to Acquire European Production Facility
Telix is pleased to announce that it has entered into a conditional purchase agreement with Eckert & Ziegler Strahlen and Medizintechnik Aktiengesellschaft to acquire a licensed radiopharmaceutical production facility in Seneffe,…
Read more